Provider: S&P Capital IQ Quantitative Report
Provider: Zacks Investment Research Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
La Jolla Pharmaceutical announces pricing of underwritten offering of common stock
La Jolla Pharmaceutical Co:Prices underwritten offering of 4,800,000 shares of its common stock, offered at a price of $10.50 per share.La Jolla has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock.Offering is expected to close on or about July 28, 2014, subject to customary closing conditions.Jefferies LLC is acting as sole book-runner for the offering.Chardan Capital Markets, LLC, H.C. Wainwright & Co., LLC, LifeSci Capital, LLC and Noble Financial Group, Inc. are acting as co-managers for the offering.Intends to use the net proceeds from the underwritten offering for general corporate purposes, including funding its ongoing and future clinical trials, and for general and administrative expenses.
Latest Developments for La Jolla Pharmaceutical Co
- La Jolla Pharmaceutical Co announces positive pre-clinical data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis
- La Jolla Pharmaceutical Co reports positive, top-line results from phase 2 clinical trial of gcs-100 in chronic kidney disease
- La Jolla Pharmaceutical Co Receives Orphan Designation From FDA
- La Jolla Pharmaceutical Co Announces FDA Acceptance Of IND For LJPC-501
- Share this
- Digg this